| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3923414 | European Urology | 2007 | 7 Pages |
Abstract
ObjectivesProvide a critical summary of the latest interpretation of findings from the Prostate Cancer Prevention Trial (PCPT).MethodsFindings from PCPT and recently published post-hoc analyses are reviewed.ResultsPCPT demonstrated that finasteride can reduce the prevalence of prostate cancer, permitted the first large-scale assessment of the performance characteristics of prostate-specific antigen for prostate cancer screening, and identified new-onset erectile dysfunction as an early predictor of cardiovascular events.ConclusionsPCPT has and will continue to yield valuable information regarding future strategies for prostate cancer prevention and detection, benign prostatic hyperplasia, and other matters of public health importance.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson,